Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone

American Journal of Drug and Alcohol Abuse

Volumn 37, Issue 4, 2011, Pages 224-228

  Bruce, R Douglas ^a   Moody, David E ^b   Fang, Wenfang B ^b   Chodkowski, Diane ^a   Andrews, Laurie ^a   Friedland, Gerald H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Buprenorphine; Glucuronide pharmacokinetics; HIV AIDS; Opioid dependence; Ritonavir; Tipranavir

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE 3 GLUCURONIDE; BUPRENORPHINE PLUS NALOXONE; CYTOCHROME P450 3A4; DRUG METABOLITE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; PLACEBO; RITONAVIR; TIPRANAVIR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY MASS; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GLUCURONIDATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; STEADY STATE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

ADULT; BUPRENORPHINE; DRUG INTERACTIONS; FEMALE; HIV SERONEGATIVITY; HUMANS; MALE; METABOLIC DETOXICATION, DRUG; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PYRIDINES; PYRONES; RITONAVIR;

EID: 79960361652     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.3109/00952990.2011.568081     Document Type: Article

References (34)

1. Bruce RD. Medical interventions for addictions in the primary care setting. Top HIV Med 2010; 18(1):8-12.
2. Bruce RD, Kresina TF, McCance-Katz EF. Medication-assisted treatment and HIV/AIDS: Aspects in treating HIV-infected drug users. AIDS 2010; 24(3):331-340.
3. Bruce RD, Altice FL. Three case reports of a clinical pharma-cokinetic interaction with buprenorphine and atazanavir plus ritonavir. AIDS 2006; 20(5):783-784. (Pubitemid 43884310)
4. Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: Implications and management for clinical practice. J Acquir Immune Defic Syndr 2006; 41(5):563-572.
5. Bruce RD, McCance-Katz E, Kharasch ED, Moody DE, Morse GD. Pharmacokinetic interactions between buprenor-phine and antiretroviral medications. Clin Infect Dis 2006; 43(Suppl. 4):S216-S223. (Pubitemid 44901889)
6. Spire B, Lucas GM, Carrieri MP. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy 2007; 18(4):262-270. (Pubitemid 47126278)
7. McCance-Katz EF, Moody DE, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Smith P, Ogundele A, Jatlow P, Rainey PM. Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin Infect Dis 2006; 43(Suppl. 4):S224-S234.
8. McCance-Katz EF, Moody DE, Smith PF, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Smith P, Ogundele A, Jatlow P, Rainey PM. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clin Infect Dis 2006; 43(Suppl. 4):S235-S246. (Pubitemid 44901891)
9. Bruce RD, Altice FL. Clinical care of the HIV-infected drug user. Infect Dis Clin North Am 2007; 21(1): 149-179. (Pubitemid 46719806)
10. Vourvahis M, Dumond J, Patterson K, Rezk N, White N, Jennings S, Tien H, Sabo J, MacGregor T, Kashuba A. Effects of tipranavir/ritonavir on the activity of hepatic and intestinal cytochrome P450 3A4/5 and P-glycoprotein: Implications for drug interactions. In 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, 2007. Foundation for Retrovirology and Human Health.
11. Kohle C, Bock KW. Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor. Biochem Pharmacol 2009; 77:689-699.
12. Product Information: Aptivus (r), tipranavir. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., 2005.
13. Baldwin JR, Borin MT, Ferry JJ, et al. Pharmacokinetic (PK) interaction between the HIV protease inhibitors tipranavir and ritonavir. In 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA: American Society of Microbiology, 1999.
14. McCallister S, Sabo J, Galitz L, Mayers D. An open-label steady state investigation of the pharmacokinetics (PK) and tipranavir (TPV) and ritonavir (RTV) and their effects on cytochrome P-450 (3A4) in normal healthy volunteers (BI 1182.5). 434-W. In 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA: Foundation for Retrovirology and Human Health. 2002.
15. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro inhibition of UDP glu-curonosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005; 33(11): 1729-1739. (Pubitemid 41539973)
16. Hanley WD, Wenning LA, Moreau A, Kost JT, Mangin E, Shamp T, Stone JA, Gottesdiener KM, Wagner JA, Iwamoto M. Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009; 53(7):2752-2755.
17. Beelen A, Balch A, Swabb E, Roalstad S, Kavitz K, Pleiman C, Smiley P, Sanguinetti E, Mather G. MPC-4326 drug-drug interaction profile. In 17th Conference on Retroviruses and Opportunistic Infections, 16-19 February 2010. San Francisco, CA, 2010. Foundation for Retrovirology and Human Health.
18. Cone EJ, Gorodetzky CW, Yousefnejad D, Buchwald WF, Johnson RE. The metabolism and excretion of buprenor-phine in humans. Drug Metab Dispos 1984; 12(5):577-581.
19. Iribarne C, Picart D, Dreano Y, Bail J-P BF. Involvement of cytochrome P450 3A4 in N-dealylation of buprenorphine in human liver micrsomes. Life Sci 1997; 60:1953-1964. (Pubitemid 27224184)
20. Moody DE, Slawson MH, Strain EC, Laycock JD, Span-bauer AC, Foltz RL. A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a co-formulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal Biochem 2002; 306:31-39. (Pubitemid 34722013)
21. Picard N, Cresteil T, Djebli N, Marquet P. In vitro metabolism study of buprenorphine: Evidence for new metabolic pathways. Drug Metab Dispos 2005; 33:689-695. (Pubitemid 40593885)
22. King CD, Green MD, Rios GR, Coffman BL, Owens IS, Bishop WP, Tephly TR. The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1. Arch Biochem Biophys 1996; 332(1):92-100. (Pubitemid 26286137)
23. Green MD, King CD, Mojarrabi B, MacKenzie PI, Tephly TR. Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos 1998; 26(6):507-512. (Pubitemid 28498354)
24. Coffman BL, King CD, Rios GR, Tephly TR. The glu-curonidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 1998; 26(1):73-77.
25. Chang Y, Moody DE. Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases. Drug Metab Lett 2009; 3: 101-107.
26. Rouguieg K, Picard N, Sauvage FL, Gaulier JM, Marquet P. Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos 2010; 38(1):40-45.
27. Huang P, Kehner GB, Cowan A, Liu-Chen L-Y. Comparison of pharmacological activities of buprenorphine and nor-buprenorphine: Norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 2001; 297(2):688-695. (Pubitemid 32378001)
28. Ohtani M, Kotaki H, Sawada Y, Iga T. Comparative analysis of buprenorphine-and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 1995; 272(2):505-510.
29. Kuhlman JJ, Jr., Levine B, Johnson RE, Fudala PJ, Cone EJ. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction 1998; 93(4):549-559. (Pubitemid 28188074)
30. Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, Friedland GH. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug Alcohol Depend 2009; 105(3):234-239.
31. Valdez H, Sabo J, Wruck J, MacGregor T, Garfinkel S, Chen L, Philip E, Mao Y, McCallister S, Norris S. Tipranavir (TPV) excretion mass balance and metabolite profile when co-administered with ritonavir (RTV). In 44th ICAAC. Washington, DC, 2004. Published by the American Society of Microbiology.
32. Huang W, Moody DE, McCance-Katz EF. The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography- electrospray ionization-tandem mass spectrometry. Ther Drug Monit 2006; 28(2):245-251. (Pubitemid 44314956)
33. Tournier N, Chevillard L, Megarbane B, Pirnay S, Scher-rmann JM, Decleves X. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol 2010; 13(7):905-915.
34. Dumond JB, Vourvahis M, Rezk NL, Patterson KB, Tien HC, White N, Jennings SH, Choi SO, Li J, Wagner MJ, La-Beck NM, Drulak M, Sabo JP, Castles MA, Macgregor TR, Kashuba AD. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther 2010; 87(6):735-742.